These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11371699)

  • 1. Long-term safety and efficacy of nevirapine, stavudine and lamivudine in a real-world setting.
    Shalit P; Farrell P; Lindgren P
    AIDS; 2001 Apr; 15(6):804-5. PubMed ID: 11371699
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine.
    Laurent C; Kouanfack C; Koulla-Shiro S; Njoume M; Nkene YM; Ciaffi L; Brulet C; Peytavin G; Vergne L; Calmy A; Mpoudi-Ngolé E; Delaporte E
    AIDS; 2007 Mar; 21(6):768-71. PubMed ID: 17413701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and tolerability of nevirapine, stavudine, and lamivudine in clinical practice.
    Yozviak JL; Doerfler RE; Woodward WC
    HIV Clin Trials; 2001; 2(6):474-6. PubMed ID: 11742435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of two different triple drug combinations in which either lamivudine or didanosine were administered with stavudine plus indinavir.
    Villalba N; Gómez-Cano M; Casas E; Soriano V; Valencia E; González-Lahoz J
    AIDS; 1997 Dec; 11(15):1896-7. PubMed ID: 9412717
    [No Abstract]   [Full Text] [Related]  

  • 5. Complete reversibility of severe nucleoside-induced lipodystrophy.
    Strobel M; Muller P; Claudel P
    AIDS; 1999 Dec; 13(18):2606-7. PubMed ID: 10630538
    [No Abstract]   [Full Text] [Related]  

  • 6. Developing countries need better antiretroviral drugs.
    Mykén N; Sundbeck B; Mpumilwa G; Andersson R
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(1):23-4. PubMed ID: 19171914
    [No Abstract]   [Full Text] [Related]  

  • 7. dNN study: stavudine, nelfinavir and nevirapine. Preliminary safety, activity and pharmacokinetic interactions.
    Skowron G
    Antivir Ther; 1998; 3 Suppl 4():61-2. PubMed ID: 10723513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda).
    Songa PM; Castelnuovo B; Mugasha EB; Ocama P; Kambugu A
    Clin Infect Dis; 2007 Aug; 45(4):514-7. PubMed ID: 17638205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe ototoxicity in a health care worker who received postexposure prophylaxis with stavudine, lamivudine, and nevirapine after occupational exposure to HIV.
    Rey D; L'Héritier A; Lang JM
    Clin Infect Dis; 2002 Feb; 34(3):418-9. PubMed ID: 11774091
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and tolerability of combination antiretroviral post-exposure prophylaxis in a population-based setting.
    Braitstein P; Chan K; Beardsell A; McLeod A; Montaner JS; O'Shaughnessy MV; Hogg RS
    J Acquir Immune Defic Syndr; 2002 Apr; 29(5):547-8. PubMed ID: 11981375
    [No Abstract]   [Full Text] [Related]  

  • 11. Renal tubular acidosis and hypophosphataemia after treatment with nucleoside reverse transcriptase inhibitors.
    Morris AA; Baudouin SV; Snow MH
    AIDS; 2001 Jan; 15(1):140-1. PubMed ID: 11192863
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection.
    Mateo MG; Gutierrez Mdel M; Vidal F; Domingo P
    Expert Opin Drug Saf; 2012 May; 11(3):473-85. PubMed ID: 22468613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon.
    Laurent C; Bourgeois A; Mpoudi-Ngolé E; Ciaffi L; Kouanfack C; Mougnutou R; Nkoué N; Calmy A; Koulla-Shiro S; Delaporte E
    AIDS Res Hum Retroviruses; 2008 Mar; 24(3):393-9. PubMed ID: 18327976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.
    Tin EE; Bowonwatanuwong C; Desakorn V; Wilairatana P; Krudsood S; Pitisuttithum P
    Southeast Asian J Trop Med Public Health; 2005 Mar; 36(2):362-9. PubMed ID: 15916042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
    Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC
    HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.
    Raffi F; Reliquet V; Francois C; Garre M; Hascoet C; Allavena C; Arvieux C; Breux JP; Perre P; Rozenbaum W; Auger S
    Antivir Ther; 1998; 3 Suppl 4():57-60. PubMed ID: 10723512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
    Reliquet V; Ferré V; Hascoet C; Besnier JM; Bellein V; Arvieux C; Molina JM; Breux JP; Zucman D; Rozenbaum W; Allavena C; Raffi F;
    Antivir Ther; 1999; 4 Suppl 3():83-4. PubMed ID: 16021876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.
    Murphy RL; Brun S; Hicks C; Eron JJ; Gulick R; King M; White AC; Benson C; Thompson M; Kessler HA; Hammer S; Bertz R; Hsu A; Japour A; Sun E
    AIDS; 2001 Jan; 15(1):F1-9. PubMed ID: 11192874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical safety of a generic fixed-dose combination of stavudine/lamivudine/névirapine (Triomune). Study of 297 cases in Togo].
    Mouhari-Touré A; Saka B; Kombat K; Tchangaï-Walla K; Pitche P
    Bull Soc Pathol Exot; 2008 Dec; 101(5):404-6. PubMed ID: 19192611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine.
    van Leth F; Hall DB; Lange JM; Reiss P
    HIV Med; 2006 Sep; 7(6):347-50. PubMed ID: 16903977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.